Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 3.43 (-0.15%)
CERT : 17.42 (-0.40%)
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results.

SGMO : 3.43 (-0.15%)
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday,...

SGMO : 3.43 (-0.15%)
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920,...

SGMO : 3.43 (-0.15%)
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920,...

SGMO : 3.43 (-0.15%)
Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect?

The consensus price target hints at a 122.2% upside potential for Sangamo (SGMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

SGMO : 3.43 (-0.15%)
Wall Street Analysts Predict a 106% Upside in Sangamo (SGMO): Here's What You Should Know

The consensus price target hints at a 106.2% upside potential for Sangamo (SGMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

SGMO : 3.43 (-0.15%)
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of 17.14% and 26.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

SGMO : 3.43 (-0.15%)
LGND : 67.73 (-0.15%)
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results.

SGMO : 3.43 (-0.15%)
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market closes on...

SGMO : 3.43 (-0.15%)

Barchart Exclusives

Shopify Hopes to Recover E-Commerce Dominance
Analysts are split on whether a rebound in Shopify Inc. (SHOP ) can be maintained. Shopify shares have tumbled +69% this year, and the average estimate of analysts is for the stock to gain only +2.2% next year. That is the lowest expected return among this year’s ten worst-performing U.S.... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar